Trevi Therapeutics Inc
TRVI
Company Profile
Business description
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Contact
195 Church Street
16th Floor
New HavenCT06510
USAT: +1 203 304-2499
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
31
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.90 | 26.70 | -0.30% |
| CAC 40 | 7,804.87 | 14.60 | 0.19% |
| DAX 40 | 24,304.46 | 19.12 | -0.08% |
| Dow JONES (US) | 42,762.87 | 443.13 | 1.05% |
| FTSE 100 | 8,837.91 | 26.87 | 0.30% |
| HKSE | 23,792.54 | 114.43 | -0.48% |
| NASDAQ | 19,529.95 | 231.51 | 1.20% |
| Nikkei 225 | 37,741.61 | 187.12 | 0.50% |
| NZX 50 Index | 12,563.48 | 13.67 | -0.11% |
| S&P 500 | 6,000.36 | 61.06 | 1.03% |
| S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
| SSE Composite Index | 3,385.36 | 1.26 | 0.04% |